|
Post by prcgorman2 on Jun 20, 2019 22:38:40 GMT -5
I don’t want to argue because I’ve been admiring what you’ve been doing for years, literally. And peppy, and liane, and mnholdem. I did read the last SO article you posted a link to on debt financing. That was a hum-dinger. Really, a very good analysis on the reasons for the 8-K and DF debt payment delay. I’m happy he gets paid by the click for that one.
I don’t feel like we’re circling the drain. I feel like we’re pulling free from quicksand. Not going anywhere fast, but we can see firmer ground and are headed in that direction (slowly). :-)
|
|
|
Post by sportsrancho on Jun 20, 2019 22:41:37 GMT -5
So check this out posted by doctorgreenback on ST
$MNKD just watched VDEX videos regarding the proposal. I’m starting to think that they submitted the proposal to the wrong company. Wouldn’t it make more sense to take this to SNY andother BPs to convince them that the drug is marketable with the VDEX strategy. At this point Afrezza sale price is low. Convince BP to buy the drug and let VDEX target a few individual states.
|
|
|
Post by sportsrancho on Jun 20, 2019 22:43:20 GMT -5
golfeveryday doctorgreenback or mnkd could partner with Vdex and show that it works then BP will want Afrezza, but at that point, mnkd would have way more leverage. Bullish
|
|
|
Post by lifebreath on Jun 20, 2019 23:28:41 GMT -5
golfeveryday doctorgreenback or mnkd could partner with Vdex and show that it works then BP will want Afrezza, but at that point, mnkd would have way more leverage. Bullish The sooner Castagna has nothing to do with Mnkd and Afrezza the sooner we will see the value of our company appreciate to the levels it should be, and Affrezza will be available to more people with diabetes
|
|
|
Post by prcgorman2 on Jun 21, 2019 6:33:20 GMT -5
And replaced with whom? You? Wild Bill? Motor-mouth? You may not appreciate what MC has accomplished and have no thought about the effort involved to have come so far with so little, but I sure do.
|
|
|
Post by sportsrancho on Jun 21, 2019 7:30:24 GMT -5
MK.........
Follow MNKD ($1.18) - Well it appears that management did not have the professional inclination to address valid concerns raised by Bill and Vdex - as I had expected. As a result, it’s time to raise the stakes and pressure here a bit. Some key institutional investors will now hear a message pertaining to management re-alignment with shareholder interests and the opportunity offered by overt consideration of strategic alternatives regarding Afrezza - strategic partnerships and also new novel approaches such as Vdex which aim to address the fundamental issues of unsustainably high customer acquisition costs and lack of financial funding. Could go on more, but will be looking to bring money to the table over the next couple of quarters to shake things up. If that means heads roll in management, that is their problem. They, not I, have brought this upon themselves. Will also expand the effort to professional proxy services such as ISS and others to go into future votes with significant momentum to build on the recent low vote on Say on Pay....Nothing personal, but this is still a $40 per share company in terms of mid term potential, but a $2 a share CEO and IR duo. Either the company changes or they change. No other way to unlock value. #MNKD
38m Michael Kovacocy Michael KovacocyAnd if this eventually results in a change of management, I will personally look to lobby new management to seek legal action on behalf of MannKind against current management for recent grants of bonuses and raises. Clawback will be a theme. Maybe nothing happens. But I can guarantee one thing - if this ends up with heads rolling and management being replaced, I will put 100% effort into making sure any excessive pay is coughed up by the CEO and gang. They should NEVER have done what they did, and they should be held to account for it.
|
|
|
Post by mnholdem on Jun 21, 2019 8:26:40 GMT -5
I don’t believe this is an idle threat and I believe that there are some powerful institutional backers involved in a shakeup of MannKind. I also want to be clear that I have no definitive proof other than my contacts, but I am of the opinion the management has erred in not seriously evaluating the present sentiment of shareholders - both retail and institutional.
I hope this can be resolved ASAP.
|
|
|
Post by matt on Jun 21, 2019 8:46:23 GMT -5
I don't know that it is possible for MNKD and Vdex to enter an agreement that sets a floor price-to-patient. Matt likely has more pricing intelligence/experience. What is a bit confusing to me is how much less will/can the price-to-patient be with the proposed arrangement? Re: my Matt comment - "Matt likely has more pricing intelligence/experience." -- mnkd.proboards.com/post/181656Yes, I do have a lot of pricing experience, especially in foreign markets. Some of the wounds have still not healed. As for MNKD setting a floor price, that is a per se violation of federal antitrust laws in this country. MNKD can set whatever price it wants to set to its distributors, but there is something known as the "first sale doctrine". Once a manufacturer has sold an item to a distributor, they may no longer control the product or its pricing in any way. In the United States before the 1970's it was permitted to have something known as "retail price maintenance" where the producer could set a floor price and insure that all retailers were charging the same price for the same product. However, this restricted discount stores from offering lower price and the laws were overturned. A manufacturer of luxury goods can still sell only to top department stores and refuse to supply Wal-Mart, but that is all they can do to prevent discounting of their brand. The term "manufacturer's suggested retail price" came about as a replacement term for the former manufacturer-dictated price. In international markets, the same applies in most places. In the EU there is an issue with the gray market for drugs because many pharmas have a higher wholesale price for drugs going into countries like Germany and a lower price for the poorer Mediterranean countries like Portugal and Greece. However, savvy pharmacy suppliers go to Portugal and buy up huge quantities of drugs and then resell them to German pharmacies and pocket the price difference. The was an EU court case on the matter and the courts ruled that the pharma manufacturers could not prevent movement of products within the common market once title had passed in Portugal.
|
|
|
Post by peppy on Jun 21, 2019 9:14:28 GMT -5
Yes, I do have a lot of pricing experience, especially in foreign markets. Some of the wounds have still not healed.As for MNKD setting a floor price, that is a per se violation of federal antitrust laws in this country. MNKD can set whatever price it wants to set to its distributors, but there is something known as the "first sale doctrine". Once a manufacturer has sold an item to a distributor, they may no longer control the product or its pricing in any way. In the United States before the 1970's it was permitted to have something known as "retail price maintenance" where the producer could set a floor price and insure that all retailers were charging the same price for the same product. However, this restricted discount stores from offering lower price and the laws were overturned. A manufacturer of luxury goods can still sell only to top department stores and refuse to supply Wal-Mart, but that is all they can do to prevent discounting of their brand. The term "manufacturer's suggested retail price" came about as a replacement term for the former manufacturer-dictated price. In international markets, the same applies in most places. In the EU there is an issue with the gray market for drugs because many pharmas have a higher wholesale price for drugs going into countries like Germany and a lower price for the poorer Mediterranean countries like Portugal and Greece. However, savvy pharmacy suppliers go to Portugal and buy up huge quantities of drugs and then resell them to German pharmacies and pocket the price difference. The was an EU court case on the matter and the courts ruled that the pharma manufacturers could not prevent movement of products within the common market once title had passed in Portugal. quote: Some of the wounds have still not healed. Reply: From memory, many times wounds that will not heal can be secondary to diabetes. Have you had your blood glucoses checked? Get the pluses in your feet checked?
|
|
|
Post by prcgorman2 on Jun 21, 2019 9:42:45 GMT -5
I don’t believe this is an idle threat and I believe that there are some powerful institutional backers involved in a shakeup of MannKind. I also want to be clear that I have no definitive proof other than my contacts, but I am of the opinion the management has erred in not seriously evaluating the present sentiment of shareholders - both retail and institutional. I hope this can be resolved ASAP. All of the other wild stuff that MK has said that didn't come true (which was all of it?) doesn't make you wonder, just a little, whether it is another idle threat?
You, sports, I, and others have been here since before FDA approval. We've had, technically, 4 CEOs in that time. Hakan Edstrom, Al Mann (briefly), Matt Pfeffer, and Mike Castagna.
The stock has been under attack since the day after FDA approval. SOMEONE (maybe several someones) wants to deny capital to Mannkind. I don't know who they are or their agenda, but I've seen their actions. The SI is often unusually high and there have been times on the SHO list. DTCC covering that level of naked shorting effectively dilutes the stock. The stock price charts provide the proof. There will be people that will say that it is the product (Afrezza) and management that are to blame for the low stock price, and all I will say is it isn't the whole story and nobody can convince me differently.
Mike Castagna and his management team, have, unequivocally, done a better job than the 3 previous CEOs.
Hakan (and Al) got screwed both by circumstances (and design?) and an inadequately buttressed global marketing agreement.
Nobody on this board anticipated UTHR and TreT. Matt and team did not bring India, Brazil, UTHR, TreT, and Afrezza sales that eclipse Sanofi with a fraction of the resources. AND, nobody, Wild Bill included, has said how much of the weekly Rx is from VDEX. If it's 90%, Wild Bill and MK may have a point. But since there's been no data and because Wild Bill looks so frighteningly desperate, I'm skeptical.
I have a couple decades of experience estimating requirements, putting plans in place, and making sure money gets spent to make things happen and have tremendous respect for what Doctors Castagna and Kendall have achieved and are achieving on a shoestring budget with an extraordinarily difficult environment for acquiring operating capital. I consider an attack on them is an effort to derail the progress that's being made and an attack on Mannkind and Mannkind shareholders.
|
|
|
Post by sportsrancho on Jun 21, 2019 11:05:37 GMT -5
I don’t believe this is an idle threat and I believe that there are some powerful institutional backers involved in a shakeup of MannKind. I also want to be clear that I have no definitive proof other than my contacts, but I am of the opinion the management has erred in not seriously evaluating the present sentiment of shareholders - both retail and institutional. I hope this can be resolved ASAP. All of the other wild stuff that MK has said that didn't come true (which was all of it?) doesn't make you wonder, just a little, whether it is another idle threat?
You, sports, I, and others have been here since before FDA approval. We've had, technically, 4 CEOs in that time. Hakan Edstrom, Al Mann (briefly), Matt Pfeffer, and Mike Castagna.
The stock has been under attack since the day after FDA approval. SOMEONE (maybe several someones) wants to deny capital to Mannkind. I don't know who they are or their agenda, but I've seen their actions. The SI is often unusually high and there have been times on the SHO list. DTCC covering that level of naked shorting effectively dilutes the stock. The stock price charts provide the proof. There will be people that will say that it is the product (Afrezza) and management that are to blame for the low stock price, and all I will say is it isn't the whole story and nobody can convince me differently.
Mike Castagna and his management team, have, unequivocally, done a better job than the 3 previous CEOs.
Hakan (and Al) got screwed both by circumstances (and design?) and an inadequately buttressed global marketing agreement.
Nobody on this board anticipated UTHR and TreT. Matt and team did not bring India, Brazil, UTHR, TreT, and Afrezza sales that eclipse Sanofi with a fraction of the resources. AND, nobody, Wild Bill included, has said how much of the weekly Rx is from VDEX. If it's 90%, Wild Bill and MK may have a point. But since there's been no data and because Wild Bill looks so frighteningly desperate, I'm skeptical.
I have a couple decades of experience estimating requirements, putting plans in place, and making sure money gets spent to make things happen and have tremendous respect for what Doctors Castagna and Kendall have achieved and are achieving on a shoestring budget with an extraordinarily difficult environment for acquiring operating capital. I consider an attack on them is an effort to derail the progress that's being made and an attack on Mannkind and Mannkind shareholders.
I don’t believe you’re listening, mnholdem is right... that doesn’t make anything you said wrong, it just doesn’t coincide with the post. Or have to do with MK. Doesn’t make it not true or not real. It’s a problem. Why are you calling people names..you’re giving people nicknames like Trump does..”wild Bill” does not it all look desperate😂 on what planet are you living :-) I can guarantee you there’s nothing desperate about him.
|
|
|
Post by buyitonsale on Jun 21, 2019 11:15:07 GMT -5
The phone is ringing... Cavalry: hello MK: Good morning gentlemen, this is Michael Kovacocy! Cavalry: Michael who MK: I would like to meet in fortnight and discuss the next act... the shake up of Mannkind... Do not mind my track record so far... Let’s grind up the pressure on management and watch the imminent rise of the stock to double digits... I have some other great ideas as well... Click
|
|
|
Post by joeypotsandpans on Jun 21, 2019 12:01:40 GMT -5
The phone is ringing... Cavalry: hello MK: Good morning gentlemen, this is Michael Kovacocy! Cavalry: Michael who MK: I would like to meet in fortnight and discuss the next act... the shake up of Mannkind... Do not mind my track record so far... Let’s grind up the pressure on management and watch the imminent rise of the stock to double digits... I have some other great ideas as well... Click That's pretty funny, I was thinking something very similar when I read his tweet/post....last time I looked, MK is no Carl Icahn, if you are an activist investor you usually have quite a bit of gun powder to make things happen...in this case whether it is MK's or Vdex's supposed gun powder it is more akin to a cap gun (anyone old enough to remember those? lol) ....I have not said anything and have been reading but will just say this for now, maybe some on here have been inhaling some cannabis but the exclusivity angle of the very public "proposal" is a non starter from the get go. Anyone that has owned or been in business should know that. My endo has been successfully prescribing A for over 3 yrs. now and his practice continues to boom (packed every appointment I go to)...he is not the only one from what I can gather. Recently while playing in a poker tournament, I sat next to a young fellow that saw me take my dose after eating....he knew what it was to my surprise (first time this has happened which should start to say a lot IMO)....turns out his wife is an up and coming endo in a large group practice in Houston...she is the youngest in the group and currently the only one prescribing A but is very encouraged by the results. He took a pic of me dosing and sent it to her as he knew she would appreciate seeing it. Btw, I have played in two events at the WSOP this year so far, I cashed in both so 2 for 2...I feel as focused as ever at the tables in the long 12 hour sessions, I will play my third this weekend, and then the Main Event July 4th weekend. Hopefully the success continues but this is the most focused and most energy I have had in quite some time so hopefully can run deep in the next two events I also attended and witnessed my younger son's graduation and receiving his PharmD last friday, we went hiking last weekend and I joined them on a six mile moderate to difficult grade hike...from that I say thank you Al and MC for your continued dedication in bringing this product to PWD. Have a great weekend all, wish me luck at the tables this weekend
|
|
|
Post by awesomo on Jun 21, 2019 12:04:10 GMT -5
Recently while playing in a poker tournament, I sat next to a young fellow that saw me take my dose after eating....he knew what it was to my surprise (first time this has happened which should start to say a lot IMO)....turns out his wife is an up and coming endo in a large group practice in Houston...she is the youngest in the group and currently the only one prescribing A but is very encouraged by the results. He took a pic of me dosing and sent it to her as he knew she would appreciate seeing it. Btw, I have played in two events at the WSOP this year so far, I cashed in both so 2 for 2...I feel as focused as ever at the tables in the long 12 hour sessions, I will play my third this weekend, and then the Main Event July 4th weekend. Hopefully the success continues but this is the most focused and most energy I have had in quite some time so hopefully can run deep in the next two events Nice, congrats! Hope to see you on TV at the final table, always been a fan of the game, though I don't play nearly as much anymore.
|
|
|
Post by buyitonsale on Jun 21, 2019 12:14:12 GMT -5
Joey, please wear an Afrezza hat when you get to the main event final table 😊
I’ll be rooting for you
|
|